Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age18+
SponsorABX advanced biochemical compounds GmbH

About this trial

This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The patient (male) is aged 18 years or above.

The patient is able to understand the information presented to him concerning the nature, scope, and consequences of the trial as set out in the information provided to the patient AND has provided written informed consent to participate.

The patient has newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment.

Overall ISUP grade group 4 or 5,

Disqualifiers

Patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection.

The patient has received any therapy - be it radiation, surgical or drug therapy - for his prostate cancer.

The patient has any contraindication(s) for and/or known hypersensitivity to any constituent(s) of [18F]PSMA-1007.

The patient is not able to have PET-CT scans (for example, because of weight, claustrophobia, or inability to lie still for the duration of the scan).

Trial design

Design model

Single group

Treatments tested in this trial

  • [18F]PSMA-1007

    Drug

    Diagnostic radiopharmaceutical for PET scan

Treatment groups

434 Participants
are divided into 1 treatment group
Group A: [18F]PSMA-1007Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Sensitivity and specificity of [18F]PSMA-1007 PET/CT for the detection of pelvic nodal disease (N1) compared to histology as the standard of reference

Time frame
6 to 8 weeks post-surgery

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.